You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK):傳奇生物在ASCO和EHA公佈CARVYKTI®用於治療多發性骨髓瘤迄今最早的資料及重要的亞組分析

格隆匯6月4日丨金斯瑞生物科技(01548.HK)發佈公吿,當地時間2024年6月3日,全球細胞治療領先者傳奇生物(NASDAQ:LEGN)在美國新澤西州薩默塞特首次公佈了針對多發性骨髓瘤患者的2期研究CARTITUDE-2隊列D的結果。資料顯示,在前線治療自體幹細胞移植(ASCT)後未達到完全緩解(CR)的患者在單次輸注CARVYKTI®聯合或不聯合來那度胺維持治療後,可獲得深度持久的緩解。這些資料已作為口頭報吿在2024年美國臨牀腫瘤學會(ASCO)年會上分享,並將在今年歐洲血液學協會(EHA)大會上再次進行口頭報吿。CARVYKTI®是首個也是唯一一款獲批用於復發或難治性多發性骨髓瘤患者二線治療的B細胞成熟抗原(BCMA)靶向療法。

美國H. Lee Moffitt癌症中心和研究所,骨髓瘤BMT-CI項目負責人Melissa Alsina博士表示:“在自體幹細胞移植治療後未獲得完全緩解的患者可能在未來的治療中經歷較短的持續緩解。這項研究結果顯示出令人鼓舞的療效,並表明了CARVYKTI®可為該患者羣體帶來的潛在獲益”。

傳奇生物首席醫學官Mythili Koneru博士表示:“我們很高興公佈CARTITUDE-2隊列D研究的結果。該結果表明CARVYKTI®對迄今最早接受治療的多發性骨髓瘤患者的顯著影響。我們相信,在多發性骨髓瘤的治療格局中,CARVYKTI®能更早地產生深度而持久的緩解,因此我們正在開展3期研究,以確定患者是否會在一線治療中獲益於CARVYKTI®。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account